198 related articles for article (PubMed ID: 14760171)
1. Drug-eluting stents: new era and new concerns.
Bhatia V; Bhatia R; Dhindsa M
Postgrad Med J; 2004 Jan; 80(939):13-8. PubMed ID: 14760171
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of drug-eluting stents: if only all things were equal.
Chew DP
Med J Aust; 2005 Apr; 182(8):376-7. PubMed ID: 15850431
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting stents: from randomized trials to the real world.
Saia F; Degertekin M; Lemos PA; Serruys PW
Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stents: cost versus clinical benefit.
Lemos PA; Serruys PW; Sousa JE
Circulation; 2003 Jun; 107(24):3003-7. PubMed ID: 12821586
[No Abstract] [Full Text] [Related]
6. Perspectives of drug-eluting stents: the next revolution.
Moses JW; Kipshidze N; Leon MB
Am J Cardiovasc Drugs; 2002; 2(3):163-72. PubMed ID: 14727979
[TBL] [Abstract][Full Text] [Related]
7. Drug-eluting stents: costs versus clinical benefit.
O'Neill WW; Leon MB
Circulation; 2003 Jun; 107(24):3008-11. PubMed ID: 12821587
[No Abstract] [Full Text] [Related]
8. Understanding the drug-eluting stent trials.
Coolong A; Kuntz RE
Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
[TBL] [Abstract][Full Text] [Related]
9. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.
van Hout BA; Serruys PW; Lemos PA; van den Brand MJ; van Es GA; Lindeboom WK; Morice MC
Heart; 2005 Apr; 91(4):507-12. PubMed ID: 15772214
[TBL] [Abstract][Full Text] [Related]
10. [Antiproliferative drug-eluting stents: systematic review of the benefits and estimate of economic impact].
Oliva G; Espallargues M; Pons JM
Rev Esp Cardiol; 2004 Jul; 57(7):617-28. PubMed ID: 15274846
[TBL] [Abstract][Full Text] [Related]
11. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
Ray GM; Nawarskas JJ; Frishman WH
Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.
Bagust A; Grayson AD; Palmer ND; Perry RA; Walley T
Heart; 2006 Jan; 92(1):68-74. PubMed ID: 15831599
[TBL] [Abstract][Full Text] [Related]
14. Drug-eluting stent: the emerging technique for the prevention of restenosis.
Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
[TBL] [Abstract][Full Text] [Related]
15. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-eluting stents in coronary artery disease.
Nawarskas JJ; Osborn LA
Am J Health Syst Pharm; 2005 Nov; 62(21):2241-51. PubMed ID: 16239414
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
18. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II.
Silber S; Hamburger J; Grube E; Pfisterer M; Belardi J; Webb J; Zmudka K; Nienaber C; Hauptman K; Rutsch W; Dawkins K; Drzewiecki J; Koglin J; Colombo A
Herz; 2004 Mar; 29(2):171-80. PubMed ID: 15057438
[TBL] [Abstract][Full Text] [Related]
19. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
